Endpoints News – Biotech and pharma business news, with a focus …
Endpoints News provides up-to-date biotech, drug, pharma, and health news for business and professional readers.
News – Endpoints News
Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3. 17 hours ago. R&D. Manufacturing.
Big dreams dominate among next-gen biotech players
Sep 22, 2024 · Here’s John Carroll’s top picks for the next-gen players of 2022 most likely to make their mark — or go down fighting for a landmark change. This marks Carroll’s 20th year …
About Endpoints News – Endpoints News
John D. Carroll is a biotech analyst and writer with decades of prize-winning experience in journalism. A co-founder of Endpoints News, he has covered biopharma for the past 20 years. …
Endpoints at #JPM22 - A look at what's to come in 2022
Endpoints has been there to chronicle it with wall-to-wall coverage, and our founder and editor John Carroll has convened top newsmakers to provide detailed insights about their strategies. …
ESMO23 | Cancer breakthroughs and barriers in oncology R&D
After a decade of patient breakthroughs leveraging technologies like immunotherapy, ADCs and targeted therapies, cancer R&D is staring down its next era. Our expert panel will look at how …
It’s mission critical this time as biotech looks to bounce back
Now it’s time to fix that. Getting together, exploring new deals, hoping someone uncorks a whopper of a buyout, all while assessing the year ahead — these are all annual traditions set …
Subscribe - Endpoints News
Endpoints Weekly Recaps the most important developments Saturday at 6 AM ET (sample issue) Post-Hoc Analysis and insight from the newsroom, plus dispatches from medical meetings and …
'Moonshot' at liver cell therapy biotech Ambys Medicines comes …
Feb 1, 2023 · Evommune raises $115M for I&I pipeline and prepares for Phase 2 results October 31, 2024. Ambys Medicines, backed by Third Rock Ventures and a partner to Takeda, closed …
Agenda: Endpoints at #JPM24
Top predictions for biotech in 2024. Catalent CEO Alessandro Maselli will be back at the big JPM healthcare confab to talk with Endpoints News founder John Carroll about their top predictions …